West Pharmaceutical Services, Inc.
WST
$263.51
-$15.59-5.59%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 766.50M | 698.00M | 748.80M | 746.90M | 702.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 766.50M | 698.00M | 748.80M | 746.90M | 702.10M |
| Cost of Revenue | 492.60M | 466.10M | 475.20M | 482.20M | 472.10M |
| Gross Profit | 273.90M | 231.90M | 273.60M | 264.70M | 230.00M |
| SG&A Expenses | 94.50M | 86.60M | 83.30M | 81.90M | 83.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 300.00K | 300.00K | 0.00 | 600.00K | -- |
| Total Operating Expenses | 606.50M | 569.30M | 577.00M | 580.20M | 572.60M |
| Operating Income | 160.00M | 128.70M | 171.80M | 166.70M | 129.50M |
| Income Before Tax | 162.00M | 113.90M | 166.90M | 168.40M | 133.20M |
| Income Tax Expenses | 30.20M | 24.10M | 36.80M | 32.40M | 21.90M |
| Earnings from Continuing Operations | 131.80M | 89.80M | 130.10M | 136.00M | 111.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 131.80M | 89.80M | 130.10M | 136.00M | 111.30M |
| EBIT | 160.00M | 128.70M | 171.80M | 166.70M | 129.50M |
| EBITDA | 201.40M | 168.70M | 212.50M | 206.90M | 168.40M |
| EPS Basic | 1.83 | 1.24 | 1.79 | 1.87 | 1.52 |
| Normalized Basic EPS | 1.44 | 1.16 | 1.52 | 1.46 | 1.15 |
| EPS Diluted | 1.82 | 1.23 | 1.78 | 1.85 | 1.51 |
| Normalized Diluted EPS | 1.44 | 1.15 | 1.51 | 1.45 | 1.14 |
| Average Basic Shares Outstanding | 72.20M | 72.50M | 72.70M | 72.80M | 73.00M |
| Average Diluted Shares Outstanding | 72.50M | 73.00M | 73.30M | 73.40M | 73.70M |
| Dividend Per Share | 0.21 | 0.21 | 0.21 | 0.20 | 0.20 |
| Payout Ratio | 11.46% | 16.93% | 11.76% | 10.66% | 13.12% |